Cancer

Subterms

    More stories

    • 125 Shares189 Views

      in Elections

      King Charles’s Cancer Diagnosis May Reshape How U.K. Monarchy Works

      by

      Britain’s king has been a highly visible royal, making hundreds of public appearances. As he steps back from view, who will fill the gap?Queen Elizabeth II liked to say that she needed to be seen to be believed. Now it falls to her son King Charles III to test that principle, after a cancer diagnosis that will force him out of the public eye for the foreseeable future.For a family that has cultivated its public image through thousands of appearances a year — ribbon-cuttings, ship launchings, gala benefits, investiture ceremonies, and so on — the sidelining of Charles may finally force the royals to rethink how they project themselves in a social-media age.The king’s illness is the latest blow to the British royal family, which has seen its ranks depleted by death (Elizabeth and her husband, Prince Philip), scandal (Prince Andrew), self-exile (Prince Harry and his wife, Meghan), and other health woes (Catherine, the wife of Prince William).Charles, who is 75, took part in 425 royal engagements in 2023, his first full year on the throne, according to a count by The Daily Telegraph. That made him the second hardest-working royal after his younger sister, Princess Anne, who did 457. Both were busier than in the previous year, when Elizabeth, though in the twilight of her life, still appeared in public sporadically.While Anne, 73, shows little sign of slowing down and William plans to return to public duties while his wife convalesces at home from abdominal surgery, even a temporary absence of the king from the public stage would put heavy pressure on the family’s skeleton crew of working royals.Princess Anne, left, during royal duties on Tuesday, giving an honor to Nicholas Spence, an operatic tenor.Yui Mok/Press Association, via Associated PressWe are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 113 Shares149 Views

      in Elections

      My Sister Chose the Day She Wanted to Die

      by

      Should terminally ill people be able to choose how they die? Six years after being diagnosed with advanced ovarian cancer, Julie Petrow-Cohen decided to use medical aid in dying — or MAID, as it is often called — to end her life. But for many Americans in similar circumstances, this is not an option. In this audio essay, the writer Steven Petrow shares the story of his sister’s last day and why MAID should be a right for everyone.Read Steven’s guest essay on Julie’s decision here.(A full transcript of this audio essay will be available by Monday.)Illustration by Akshita Chandra/The New York Times; Photograph by Steven PetrowThe Times is committed to publishing a diversity of letters to the editor. We’d like to hear what you think about this or any of our articles. Here are some tips. And here’s our email: letters@nytimes.com.Follow the New York Times Opinion section on Facebook, X (@NYTOpinion) and Instagram.This episode of “The Opinions” was produced by Derek Arthur. It was edited by Kaari Pitkin. Mixing by Sonia Herrero. Original music by Isaac Jones, Carole Sabouraud and Pat McCusker. Fact-checking by Mary Marge Locker. Audience strategy by Kristina Samulewski and Shannon Busta. Special thanks to Joanna Pearlstein, Hans Buetow and the “Modern Love” podcast team. More

    • 188 Shares179 Views

      in US Politics

      Katie Porter lambasts big pharma over cancer drug price hike using whiteboard calculations – video

      by

      Play Video

      3:02

      US representative Katie Porter used her now-signature whiteboard as she questioned former Celgene CEO Mark Alles over the connection between the significant price hike for Revlimid, a common cancer drug, and his personal bonus.
      The Democratic congresswoman for California presented her argument during a House oversight and reform committee hearing that centred on an 18-month investigation into pharmaceutical price gouging. The drug makers defended the price rises as the cost of doing research and development and talked about price-reduction programmes their companies offer
      Congresswoman Katie Porter secures free coronavirus testing for all Americans – video

      Topics

      Pharmaceuticals industry

      Cancer

      US politics More